Diagnostics
Ariba & Mac provides CMC consulting, CDMO selection and technology-transfer support for pharmaceutical and biotechnology programs moving from development toward GMP manufacturing and commercialization. We connect process design, analytical methods, manufacturing strategy, quality documentation and regulatory CMC requirements in one coordinated plan.
The highest-risk CMC gaps often appear at scale-up: a process that works in the development lab may not reproduce at the receiving site, analytical methods may not be transfer-ready, vendors may have capability gaps, and CMC documentation may lag behind the actual process. We address these dependencies before they become batch failures, submission deficiencies or costly transfer delays.
For Saudi manufacturing and localization projects, CMC planning should consider the intended receiving site, SFDA expectations, technology-transfer readiness and the evidence needed to operate a controlled commercial process. Our model can coordinate Saudi objectives with international CMC requirements when the product is also intended for other regulated markets.
CMC Development, CDMO Selection & Technology Transfer Deliverables
The CMC workstream is built around manufacturability, reproducibility, product quality and the documentation needed to demonstrate control throughout the product lifecycle.
- CMC strategy and gap assessment aligned to the product stage, dosage form, target market and intended manufacturing route.
- CMO/CDMO/CRO identification, technical comparison, qualification support, contracting inputs and performance oversight.
- Pilot, engineering, validation and commercial-manufacturing planning under the applicable GMP quality system.
- Process design and development, optimization, scale-up and technology-transfer planning using risk-based and Quality-by-Design principles where appropriate.
- Analytical method development, transfer, validation and lifecycle planning linked to product specifications and stability requirements.
- Batch records, stability programs, specifications, validation records and quality documentation required to maintain process control.
- CMC module and technical-document preparation for applicable IND/IMPD/NDA/BLA/MAA/eCTD/DMF or regional submission pathways.
CMC Strategy & Development Control
Define the process, analytical, stability and documentation work needed to reach the next manufacturing or regulatory milestone without losing sight of commercial-scale requirements.
CDMO Selection & Oversight
Compare technical capability, quality maturity, capacity, timelines, commercial assumptions and transfer requirements before a partner is selected and throughout delivery.
Scale-Up, Validation & Technology Transfer
Translate development knowledge into a controlled receiving-site package covering methods, materials, equipment considerations, process parameters, validation and change management.
CMC Development & Technology Transfer Process from Scale-Up to Manufacturing
We use decision gates to expose manufacturing and documentation risks early, then coordinate partner execution so process changes, analytical work, quality controls and regulatory documentation stay synchronized.
- Establish the current CMC baseline, critical gaps, target manufacturing model, product specifications, stability status and regulatory milestones before committing to a transfer or vendor.
- Track technical changes, validation evidence, deviations, quality agreements and submission-impacting decisions through a controlled governance process.
1. CMC Gap Assessment & Manufacturing Strategy
Review development data, process and analytical maturity, stability, specifications, manufacturing options and partner requirements; then define the sequence of work needed for scale-up and transfer.
2. Transfer, Validation & Submission Readiness
Coordinate the selected manufacturing partner, method and process transfer, qualification/validation activities, manufacturing documentation and CMC updates through the agreed regulatory milestone.
Integrated CMC Consulting to Reduce Scale-Up and CDMO Risk
CMC problems rarely sit in one function. A manufacturing change can affect analytics, stability, validation, quality records and regulatory documentation. Integrated oversight makes those dependencies visible before a decision is locked in.
Technology Transfer with Context
The receiving site gets more than a document handoff: process history, critical parameters, method status, known risks and validation expectations are coordinated as part of the transfer.
Regulatory CMC Continuity
Technical changes are reviewed for their effect on the CMC narrative and supporting documentation so the submission package reflects the process that is actually being developed or manufactured.
Quality & Vendor Governance
Quality agreements, audits, CAPA, change control, KPIs and risk registers provide practical controls for outsourced manufacturing and testing relationships.
Pharmaceutical Manufacturing Readiness Beyond Batch Success
A transfer or scale-up is considered in the context of reproducibility, analytical control, documentation, validation, quality governance and the intended regulatory pathway. We do not present a vendor selection or successful pilot batch as a guarantee of regulatory approval or commercial success.
Authoritative Regulatory, Government & Academic Resources
For current official requirements, standards and sector guidance, consult the relevant authority directly. These independent external resources are provided for reference and do not imply affiliation or replace project-specific regulatory, legal or clinical advice.
- SFDA Good Manufacturing Practice (GMP) Guidelines — Official Saudi GMP guidance relevant to pharmaceutical manufacturing and quality systems.
- ICH Quality Guidelines — International harmonized guidance covering CMC development, pharmaceutical quality and lifecycle management.
- SFDA Pharmaceutical Manufacturer & Product Registration Rules — Official Saudi rules for registration of pharmaceutical manufacturers and products.
FAQs About CMC Development, CDMO Selection & Technology Transfer
CMC consulting can cover process and analytical strategy, manufacturing readiness, stability, specifications, validation, quality documentation, CDMO management, technology transfer and the technical content needed for regulatory submissions.
We compare technical fit, quality systems, equipment and capacity, development or manufacturing experience, timelines, commercial assumptions and transfer requirements, then support qualification and governance for the selected partner.
Yes. The transfer can be structured around the receiving site’s equipment, methods, materials, quality system and SFDA-related requirements, with a documented plan for knowledge transfer, verification and validation.
We can coordinate and prepare CMC technical content and supporting documentation for the applicable pathway, using the actual process, analytical, stability and quality evidence available for the program.
There is no reliable fixed timeline. Product complexity, existing process knowledge, analytical maturity, stability data, vendor readiness, validation needs and authority milestones all affect the schedule. We establish a stage-gated plan after the CMC baseline is reviewed.
Yes. A focused gap assessment can identify the critical technical, vendor, quality and documentation dependencies, after which the recovery plan can prioritize activities that directly affect the next manufacturing or regulatory milestone.